Medline (NASDAQ:MDLN) Stock Price Expected to Rise, UBS Group Analyst Says

Medline (NASDAQ:MDLN) had its price objective increased by UBS Group from $48.00 to $57.00 in a research report issued on Thursday,Benzinga reports. The firm currently has a “buy” rating on the stock. UBS Group’s target price points to a potential upside of 19.97% from the stock’s previous close.

A number of other analysts also recently issued reports on MDLN. BMO Capital Markets lifted their price target on Medline from $45.00 to $54.00 and gave the stock an “outperform” rating in a report on Thursday. Rothschild & Co Redburn set a $42.00 target price on Medline in a research note on Monday, January 12th. Piper Sandler initiated coverage on Medline in a report on Monday, January 12th. They issued an “overweight” rating and a $50.00 price target for the company. JPMorgan Chase & Co. set a $55.00 price target on shares of Medline in a research note on Wednesday, January 21st. Finally, TD Cowen assumed coverage on shares of Medline in a report on Monday, January 12th. They set a “buy” rating on the stock. Two equities research analysts have rated the stock with a Strong Buy rating, twenty-one have given a Buy rating and five have issued a Hold rating to the stock. Based on data from MarketBeat.com, Medline presently has an average rating of “Moderate Buy” and an average target price of $50.35.

Medline Trading Down 2.8%

Shares of NASDAQ:MDLN opened at $47.51 on Thursday. Medline has a 52 week low of $34.89 and a 52 week high of $50.88. The firm has a 50 day moving average price of $44.52.

Medline (NASDAQ:MDLN) last released its quarterly earnings data on Wednesday, February 25th. The company reported ($0.01) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.24 by ($0.25). The firm had revenue of $7.79 billion for the quarter, compared to analyst estimates of $7.52 billion. Medline’s revenue was up 14.8% compared to the same quarter last year.

Insiders Place Their Bets

In other Medline news, major shareholder Hellman & Friedman Capital Par sold 6,088,371 shares of the business’s stock in a transaction that occurred on Thursday, December 18th. The stock was sold at an average price of $28.37, for a total value of $172,727,085.27. Following the completion of the sale, the insider owned 4,806,160 shares in the company, valued at approximately $136,350,759.20. The trade was a 55.88% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Charles N. Mills bought 2,579,310 shares of the business’s stock in a transaction dated Thursday, December 18th. The stock was acquired at an average cost of $29.00 per share, for a total transaction of $74,799,990.00. Following the completion of the acquisition, the director directly owned 2,441,379 shares in the company, valued at approximately $70,799,991. This trade represents a -1,870.00% increase in their ownership of the stock. The disclosure for this purchase is available in the SEC filing.

Institutional Investors Weigh In On Medline

A number of institutional investors and hedge funds have recently made changes to their positions in the business. Employees Retirement System of Texas acquired a new position in Medline in the 4th quarter valued at about $1,820,000. Entrust Financial LLC acquired a new position in shares of Medline in the fourth quarter valued at approximately $26,000. Charles Schwab Investment Management Inc. purchased a new stake in shares of Medline during the fourth quarter worth approximately $32,762,000. Comerica Bank purchased a new position in Medline in the 4th quarter valued at $204,000. Finally, UBS Group AG acquired a new position in Medline in the 4th quarter valued at $54,707,000.

Key Medline News

Here are the key news stories impacting Medline this week:

• Positive Sentiment: Citigroup raised its price target to $60 and kept a “buy” rating — a ~26.6% upside from the recent price, highlighting conviction after the quarter. Citigroup Raise
• Positive Sentiment: UBS increased its target to $57 and maintained a “buy” rating — ~20.2% upside — reflecting upgraded forecasts post-Q4. UBS Raise
• Positive Sentiment: BMO lifted its target to $54 and set an “outperform” rating (~13.9% upside), joining other brokers in boosting estimates after the quarter. BMO Raise
• Positive Sentiment: RBC raised its target to $53 with an “outperform” call (~11.8% upside), another vote of confidence from the street. RBC Raise
• Neutral Sentiment: Analysts broadly boosted forecasts after Q4 results; summary coverage aggregates the upgrades and modeling adjustments. Analysts Boost Forecasts
• Neutral Sentiment: Medline’s Q4 earnings call highlighted record sales and strategic innovations — supportive for revenue trajectory but mixed vs. EPS expectations. Earnings Call Highlights
• Neutral Sentiment: Full earnings call transcript is available for investors who want detail on guidance, margin commentary and management tone. Earnings Transcript
• Neutral Sentiment: Wells Fargo raised its target slightly to $47 but kept an “equal weight” rating — effectively neutral near-term guidance from this shop. Wells Fargo Note
• Negative Sentiment: Shares gapped down after what coverage labels a weak earnings print (EPS miss despite a revenue beat), which prompted the initial selloff. Shares Gap Down
• Negative Sentiment: As Medline transitions to public markets, the IPO/ESOP disclosures and management’s growth guidance drew public scrutiny — a source of near-term uncertainty for investors. IPO Scrutiny

About Medline

Medline (NASDAQ: MDLN) is a healthcare products and services company that manufactures, sources and distributes a wide range of medical supplies and equipment for healthcare providers. Its product portfolio spans clinical consumables and personal protective equipment, surgical and procedural supplies, wound care and incontinence products, diagnostic and laboratory supplies, and select durable medical equipment. Medline supports care settings that include hospitals, health systems, long-term care facilities, ambulatory clinics and home health providers.

In addition to product manufacturing and distribution, Medline provides supply‑chain and logistics services designed to help healthcare customers manage inventory, reduce costs and streamline operations.